Prognostic Risk Factors in the HR-NBL-1/SIOPEN Study in Patients Receiving Dinutuximab Beta (DB) Based ImmunotherapyR. Ladenstein,U. Poetschger,D. Valteau-Couanet,J. Gray,R. Luksch,W. Balwierz,V. Castel,S. Ash,M. Beck-Popovic,G. Laureys,G. Chi Fung Chan,E. Ruud,K. Vettenranta,C. Owens,H. Schroeder,P. Ambros,S. Sarnacki,T. Boterberg,H. LodePEDIATRIC BLOOD & CANCER(2020)引用 0|浏览11暂无评分AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要